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Background: Interleukin 1 (IL-1) is implicated in neuroinflammation, an essential component of neurodegeneration.
We evaluated the potential anti-inflammatory effect of a novel peptide antagonist of IL-1 signaling, Ilantide.
Methods: We investigated the binding of Ilantide to IL-1 receptor type I (IL-1RI) using surface plasmon resonance, the
inhibition of Il-1β-induced activation of nuclear factor κB (NF-κB) in HEK-Blue cells that contained an IL-1β-sensitive
reporter, the secretion of TNF-α in macrophages, protection against IL-1-induced apoptosis in neonatal pancreatic islets,
and the penetration of Ilantide through the blood–brain barrier using competitive enzyme-linked immunosorbent assay
(ELISA). We studied the effects of the peptide on social behavior and memory in rat models of lipopolysaccharide
(LPS)- and amyloid-induced neuroinflammation, respectively, and its effect in a rat model of experimental autoimmune
enchephalomyelitis.
Results: Ilantide bound IL-1RI, inhibited the IL-1β-induced activation of NF-κB, and inhibited the secretion of TNF-α
in vitro. Ilantide protected pancreatic islets from apoptosis in vitro and reduced inflammation in an animal model of
arthritis. The peptide penetrated the blood–brain barrier. It reduced the deficits in social activity and memory in
LPS- and amyloid-treated animals and delayed the development of experimental autoimmune enchephalomyelitis.
Conclusions: These findings indicate that Ilantide is a novel and potent IL-1RI antagonist that is able to reduce
inflammatory damage in the central nervous system and pancreatic islets.
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Pancreatic isletsIntroduction
Interleukin 1 (IL-1) is a key mediator of the acute-phase
inflammatory response and has been implicated as
the mediator of tissue dysfunction and destruction in
chronic inflammatory diseases such as amyotrophic lat-
eral sclerosis, diabetes and rheumatoid arthritis. IL-1 is
also believed to mediate neuroinflammation in neurode-
generative conditions, including Alzheimer’s disease
(AD) [1]. IL-1 signals via IL-1 receptor type I (IL-1RI),
which binds both the IL-1α and IL-1β isoforms [2].
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distribution, and reproduction in any mediumprotein (IL-1RAcP) is recruited, allowing nuclear factor
κB (NF-κB) and mitogen-activated protein kinase
(MAPK) signaling to trigger the expression and release
of a multitude of inflammatory mediators, including
chemokines and cytokines. IL-1 antagonists encompass
IL-1 receptor antagonist (IL-1Ra), IL-1-neutralizing anti-
bodies and the IL-1 trap, a linear fusion protein between
the soluble IL-1 receptor (sIL-RI) and IL-1RAcP. IL-1Ra
binds to IL-1RI, but it does not initiate signaling, be-
cause it does not engage IL-1RAcP [3,4]. These biologics
are indicated for the treatment of autoinflammatory dis-
eases and rheumatoid arthritis and have shown promising
results in clinical trials for other inflammatory conditions.
Anakinra (Ana) is a recombinantly produced protein that
contains the N-terminal, methionylated, nonglycosylated
version of human IL-1Ra, which competitively blocks thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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Ana has been used for the treatment of rheumatoid arth-
ritis, adult-onset Still’s disease, systemic onset juvenile
idiopathic arthritis, osteoarthritis and type 2 diabetes mel-
litus [5,6]. However, the relatively poor penetration of the
blood–brain barrier (BBB) [7] restricts therapeutic use of
the current macromolecular IL-1 antagonist proteins for
the treatment of neuroinflammation [8].
In the present study, we identified and characterized a
novel synthetic peptide, ten amino acids long, termed
Ilantide, which is derived from the human IL-Ra N-ter-
minal domain involved in interactions with IL-1RI. We
hypothesized that Ilantide would compete with IL-1R
signaling, thereby inhibiting inflammatory responses in-
duced by various conditions in vitro and in vivo. Indeed,
we found that Ilantide bound to IL-1RI and inhibited
the IL-1-induced activation of NF-κB and secretion of
tumor necrosis factor α (TNF-α) by macrophages. It
protected pancreatic islets from IL-1β-induced apoptosis
and reduced inflammation in collagen-induced arthritis
(CIA). The peptide penetrated the BBB, ameliorated
decline in social activity and memory in lipopolysacchar-
ide (LPS)- and amyloid-treated animals and delayed the
development of experimental autoimmune encephalo-
myelitis (EAE).
Materials and methods
Peptides and recombinant proteins
The Ilantide peptide (SGRKSSKMQA), scrambled peptide1
(KQSAGKRSMS), scrambled peptide2 (KASQKGMSRS)
and Ilantide peptide with a reversed sequence (AQMK
SSKRGS) were purchased from Schafer-N (Copenhagen,
Denmark). The peptides were synthesized using the fluore-
nylmethyloxycarbonyl protection strategy on TentaGel
resin (Rapp Polymere, Tübingen, Germany). The peptides
were synthesized as either monomers (Ilantide-m) or den-
drimers composed of four monomers coupled to a lysine
backbone (Ilantide-t) and were further purified by gel
filtration using Sephadex G-10 (Amersham Biosciences,
Uppsala, Sweden). The peptides were at least 85% pure ac-
cording to estimation by high-performance liquid chroma-
tography. The recombinant proteins (that is, IL-1β, IL-6,
TNF-α, interferon γ (IFN-γ), IL-1Ra and the ectodomain of
IL-1RI) were purchased from R&D Systems (Minneapolis,
MN, USA). Ana (Kineret) was obtained from Amgen
(Thousand Oaks, CA, USA).
Surface plasmon resonance analysis
The binding analysis was performed using a Biacore
2000 instrument (GE Healthcare Life Sciences) that
contained 150 mM NaCl as running buffer at 25°C with
10 mM sodium phosphate (pH 7.4). The flow rate was 5
μl/min during immobilization. Ilantide peptide, IL-1β or
IL-1Ra was immobilized on a CM4 sensor chipaccording to the manufacturer’s instructions, after which
the recombinant ectodomain of IL-1RI (R&D Systems)
was injected. The neural cell adhesion molecule
(NCAM) immunoglobulin modules 1 and 2 (Ig1 and
Ig2) were used as a negative control protein [9]. The
data were analyzed using nonlinear curve-fitting with
the manufacturer’s software.
Cell cultures
HEK-Blue IL-1β cells that contained an IL-1β-sensitive re-
porter (InvivoGen, San Diego, CA, USA) and HEK-Blue
IL-6 cells that contained an IL-6-sensitive reporter (Invi-
voGen) were grown at 37°C with 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5%
(vol/vol) fetal calf serum (FCS), 4.5 g/L glucose, 2 mM
GlutaMAX medium, 100 U/ml penicillin, 100 μg/ml
streptomycin (all obtained from Gibco BRL/Life Tech-
nologies, Taastrup, Denmark), 100 μg/ml zeocin, 200
μg/ml hygromycin and 100 μg/ml Normocin (all pur-
chased from InvivoGen).
A murine alveolar macrophage cell line, AMJ2-C8
(American Type Culture Collection, Borås, Sweden), was
routinely grown at 37°C with 5% CO2 in DMEM supple-
mented with 5% (vol/vol) FCS, 0.5% (v/v) 2-[4-(2-hydro-
xyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) (Gibco
BRL), 2 mM GlutaMAX, 100 U/ml penicillin and 100 μg/
ml streptomycin.
Cerebellar granule neurons (CGNs) were prepared
from 7-day-old Wistar rats (from Charles River Labora-
tories, Sulzfeld, Germany; or from Hygind Møllegård
Erik Møllegaard Hansen, Ejby, Denmark) as previously
described [10]. Briefly, the cerebella were cleared of
meninges and blood vessels, roughly homogenized by
chopping and trypsinized. The cells were washed in the
presence of DNAse I and soybean trypsin inhibitor
(Sigma-Aldrich, St Louis, MO, USA), and cellular debris
was pelleted by centrifugation. The fibroblastoid mouse
cell line L929 (LVN; European Collection of Cell Cul-
tures, Porton Down, UK) was routinely grown at 37°C
with 5% CO2 in DMEM supplemented with 10% (vol/
vol) FCS, 2 mM GlutaMAX, 100 U/ml penicillin and
100 μg/ml streptomycin.
Rat islet isolation and culture
Neonatal rat islets were isolated from 3- to 6-day-old
outbred Wistar rats (Taconic, Ejby, Denmark) as previ-
ously described [11]. Islets were precultured and main-
tained in RPMI 1640 medium (Gibco/Life Technologies)
supplemented with 20 mmol/L HEPES buffer, 0.038%
(wt/vol) NaHCO3, 100 U/ml penicillin, 100 g/ml strepto-
mycin and 10% (vol/vol) newborn calf serum (NCS) at
37°C in humidified atmospheric air. Prior to experimen-
tation, the islets were randomly distributed to 24-well
dishes and incubated for 2 hours in RPMI 1640 medium
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NCS relevant reagents were added as indicated.
Nuclear factor κB activation
HEK-Blue IL-1β cells allow the monitoring of the activa-
tion of the NF-κB pathway specifically in response to
IL-1β. They express a NF-κB-inducible secreted embry-
onic alkaline phosphatase (SEAP) reporter gene. The
binding of IL-1β to its receptor IL-1RI on the surface of
HEK-Blue IL-1β cells triggers a signaling cascade that
leads to the activation NF-κB and the subsequent pro-
duction of SEAP. HEK-Blue IL-1β cells were grown as
described above. The cells were seeded onto a 96-well
plate at a density 3.5 × 105 cells/ml. For the NF-κB acti-
vation assay, the cells were treated with 1.2 pM IL-1β
alone or together with sIL-1RI, IL-1Ra or various con-
centrations of Ilantide. After 24 hours of incubation at
37°C, 150 μl of the cell supernatants were added to each
well of a 96-well plate together with 50 μl of QUANTI-
Blue (InvivoGen), incubated at 37°C for 40 minutes and
measured in an enzyme-linked immunosorbent assay
(ELISA) reader at 600 nm to determine the expression
levels of reporter genes activated by NF-κB.
Signal transducer and activator of transcription 3
activation
HEK-Blue IL-6 cells were grown as described above. IL-6
cells allow the monitoring of the activation of the signal
transducer and activator of transcription 3 (STAT3) path-
way specifically in response to IL-6. They express a
STAT3-inducible SEAP reporter gene. For the STAT3 acti-
vation assay, the cells were treated with 1.2 pM IL-6 alone
or together with various concentrations of Ilantide. TNF-α
(1.2 pM) was added as a control ligand for both the NF-κB
and STAT3 assays. After 24-hour incubation at 37°C, 150
μl of HEK-Blue cell supernatant were added to each well of
a 96-well plate together with 50 μl of QUANTI-Blue (Invi-
voGen), incubated at 37°C in the dark for 40 minutes and
measured in an ELISA reader at 600 nm to determine the
expression level of the secreted SEAP.
Tumor necrosis factor α secretion
AMJ2-C8 macrophages were seeded into six-well mul-
tidishes at a density of 2.5 × 105 cells/well, and sIL-1RI,
IL-1Ra or various concentrations of Ilantide were added
to the cultures. Treatment with 100 μM hydrocortisone
(Sigma-Aldrich, Brøndby, Denmark) was used as a posi-
tive control. After 10-minute incubation at 37°C, 1.2 pM
IL-1β or IFN-γ (R&D Systems) was added to activate the
macrophages. L929 cells were seeded onto a 96-well
plate (Nunc, Roskilde, Denmark) at a density 0.2 × 102
cells/ml. Both cell cultures were incubated for 24 hours
at 37°C. Conditioned medium from macrophages was
collected and added to the L929 cell cultures togetherwith actinomycin D (0.6 μg/well; Sigma-Aldrich). TNF-α
is known to induce classic apoptosis in L929 cells
in the presence of actinomycin D [12]. After 24-hour
incubation at 37°C, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium (Promega, Madison, WI, USA) were added to
each well and incubated at 37°C in the dark for 45 mi-
nutes, then measured in an ELISA reader at 490 nm. To
calculate the amount of TNF-α in the conditioned
medium, fibroblasts were treated with standard concen-
trations of TNF-α (R&D Systems).
Cell survival and apoptosis
Pancreatic islets and nitric oxide production
For cell death detection, rat islets were incubated with
150 pg/ml IL-1β (BD Pharmingen, San Diego, CA, USA)
alone or in combination with various concentrations of
Ana and Ilantide for 24 hours at 37°C in humidified at-
mospheric air. Rat islet cell death was assessed by cell
death detection ELISA (Roche, Lund, Sweden) as previ-
ously described [13]. As a surrogate measure of nitric
oxide production, Griess reagent (1:1 aqueous mixture
of 0.1% naphthylethylenediamine hydrochloride and 1%
sulfanilamide + 5% H3PO4) was mixed in a 1:1 ratio with
100 μl of supernatant samples to determine the nitrite
content in supernatants from the cell death assays de-
scribed above.
Primary neurons
Cerebellar granule neurons were plated at a density of
1 × 105 cells/cm2 on poly-L-lysine-coated, eight-well
Permanox Lab-Tek chamber slides (Nunc) in Neurobasal-A
medium supplemented with 2% (vol/vol) B27 (Gibco BRL),
0.5% (vol/vol) GlutaMAX, 100 U/ml penicillin and
100 μg/ml streptomycin. The CGN survival assay was per-
formed as previously described [14]. The neurite outgrowth
assay was also performed as previously described [15].
Animal studies
Male Wistar rats (Charles River Laboratories) weighing
150 to 200 g on the day of arrival in the laboratory were
housed two per cage. Juvenile rats (3 weeks old, weight
40 to 50 g) were housed in groups of three. All of the
animals were kept under standard conditions (23°C, 50%
humidity, 12:12-hour light-dark cycle) with free access
to food and water. All of the experiments were per-
formed according to European Union legislation with
licenses from the Danish Animal Experiments Inspector-
ate (2008/561-1539, 2008/561-1524 and 2009/561-1686).
The number of animals utilized in the respective experi-
mental groups was kept to a minimum, and all of the
work was conducted in a manner designed to cause the
least harm and suffering to the animals.
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Biotinylated Ilantide-t (Schafer-N) was administered to
adult male Wistar rats subcutaneously (s.c.) at a dose
of 10 mg/kg. Twenty minutes, sixty minutes, one hun-
dred forty minutes, five hours and thirty hours after pep-
tide administration, blood samples (approximately 300
μl) were collected from the orbital plexus under fen-
tanyl/droperidol/midazolam anesthesia (0.002%/0.14%/
0.014% wt/vol) (Department of Experimental Medicine,
University of Copenhagen, Denmark) in ethylenedi-
aminetetraacetic acid–coated tubes (BD, Plymouth, UK),
and 50 to 110 U/ml aprotinin (Calbiochem, San Diego,
CA, USA) was added immediately to the collected blood.
The samples were subsequently centrifuged at 1,500 × g
for 15 minutes. Cerebrospinal fluid (CSF) was collected
from the cisterna magna 30 minutes after peptide ad-
ministration as described previously [16]. Plasma and
CSF samples were stored at −80°C.
The concentrations of Ilantide-t in plasma and CSF
samples were measured by performing a competitive
ELISA on amino 96-well plates (Nunc). The bottoms of
the wells were coated with biotinylated bovine serum al-
bumin (Sigma-Aldrich) diluted in coating buffer (0.1 M
Na-carbonate buffer, pH 9.6) to a concentration of
1 μg/ml, and 100 μl were applied to each well. The
plates were incubated overnight at 4°C and then washed
three times in washing buffer (PBS with 0.1% vol/vol
Tween 20, pH 7.4). One volume of diluted sample or a
standard with a known concentration of the biotin-labeled
Ilantide was pipetted into the wells of a mixing Protein
LoBind Eppendorf Plate (Eppendorf, Hamburg, Germany)
and incubated with three volumes of streptavidin-peroxidase
(Dako Denmark A/S, Glostrup, Denmark) diluted
1:10,000 in washing buffer. After preincubation for 30
minutes, 100 μl of the resulting incubation mixture
were transferred onto the prepared ELISA plate and
then incubated for 1 hour at 37°C. The plate was
then washed three times in washing buffer, and
3,3′,5,5′-tetramethylbenzidine substrate (Kem-En-Tec
Diagnostics, Taastrup, Denmark) was added (100 μl/well)
for 5 to 10 minutes at room temperature. Color develop-
ment was terminated by the addition of 2 M H2SO4
(100 μl/well), and absorbance was read at 450 nm on
a Wallac Victor 1420 multilabel counter (PerkinElmer,
Hvidovre, Denmark). Peptide concentrations in the samples
were determined using a standard curve. Samples from four
to six animals were used for each time point and run in
duplicate. Two independent determinations were performed.
Collagen-induced arthritis in rats
CIA was induced by bovine collagen type II (CII; Sigma-
Aldrich) solubilized in 0.05 M acetic acid (2 mg/ml),
then emulsified 1:1 with complete Freund’s adjuvant
(CFA) (Sigma-Aldrich) that contained 1.0 mg/ml heat-inactivated Mycobacterium tuberculosis. While the ani-
mals were under inhalation anesthesia (3% isoflurane;
Baxter, Allerød, Denmark), 250 μl of the emulsion that
contained 250 μg of CII and 125 μg of M. tuberculosis
were injected intradermally at the tail base (day postim-
munization 0 (dpi 0)). On dpi 8, before the onset of clin-
ical signs, all of the animals were randomly divided into
two groups, with 20 rats per group, and dosed daily for
8 days (dpi 8 to 15) with Ilantide s.c. (10 mg/kg) or ve-
hicle s.c. (1.0 ml/kg PBS). Clinical evaluations were per-
formed on dpi 7 to 16. An observer who was blinded to
the treatment groups evaluated the severity of arthritis
by employing the following grading system: 0 (no red-
ness or swelling of the foot), 1 (slight redness in the foot
or redness and swelling in single interphalangeal joints),
2 (moderate swelling and redness in the ankle and meta-
tarsal part of the foot), 3 (marked swelling and redness
of the entire foot, with restricted use of the foot during
locomotion) and 4 (marked swelling and redness of the
entire foot, with no use of the foot during locomotion).
CIA typically involves only the hindlimbs, and the arth-
ritic index was defined as the sum of the two limb
scores. The animals were killed when the severity of
arthritis reached a score of 7. The differences in the area
under the clinical score curve during the period of
observation between the control and peptide-treated
groups were calculated, with baseline defined as the start
of treatment (that is, 0).
Lipopolysaccharide-induced impairment of social behavior
The peripheral administration of LPS, the active frag-
ment of bacterial endotoxin, results in an increase in the
plasma levels of all proinflammatory cytokines and be-
havioral depression [8]. LPS-induced behavioral depres-
sion was assessed by measuring the reduction of the
duration of social interaction during 4-minute sessions.
Six- to seven-week-old rats were handled for five days,
habituated to the test cages and the experiment room
and trained for social interaction with three-week-old ju-
venile rats introduced into the test cage for four minutes
two days before the actual experiment. On the day of
the experiment, the rats were intraperitoneally injected
(i.p.) with saline or LPS (Escherichia coli 0111:B4;
Sigma-Aldrich) dissolved in saline (250 μg/kg). Immedi-
ately after the i.p. injection, Ilantide-t (Ila; 10 mg/kg,
equivalent to 2.1 μmol/kg), Ana (100 mg/kg, equivalent
to 5.8 μmol/kg) or saline was injected subcutaneously.
The volume of all of the injections was 1.0 ml/kg. Six
experimental groups were used: vehicle i.p./vehicle s.c.
(veh/veh; n = 10), vehicle i.p./Ilantide-t s.c. (veh/Ila;
n = 8), vehicle i.p./Ana s.c. (veh/Ana; n = 9), LPS i.p./ve-
hicle s.c. (LPS/veh; n = 10), LPS i.p./Ilantide-t s.c. (LPS/
Ila; n = 11) and LPS i.p./Ana s.c. (LPS/Ana; n = 11). The
injections and weighing of the rats were performed
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mals were tested and weighed again 2, 4, 6, 8, and 24 hours
later. Different juvenile animals were presented on each oc-
casion. Social interaction consisted of anogenital sniffing,
licking and chewing the fur of the juveniles by the experi-
mental animals and was monitored with a video camera.
Animals that showed less than 40 seconds of investigation
of the juveniles during the baseline session were excluded.
The duration of social interaction at each time point is
expressed as the percentage of baseline values and was av-
eraged for each experimental group. Social interaction was
scored by an observer who was blinded to the treatment of
the animals. For evaluation of levels of pro- and anti-
inflammatory cytokines in blood, rats were injected with
LPS and then immediately with either vehicle (n = 8) or
Ilantide-t (n = 8) as described above. In addition, a control
group of animals (n = 4) was treated with Ilantide-t alone
(control). Blood samples were collected at 0, 2 and 6 hours
after injections as described for the pharmacokinetics study
and stored at −20°C until use. The levels of IL-6, IFN-γ
and IL-10 were determined using corresponding rat ELISA
kits according to the manufacturer’s protocols (all from BD
Biosciences, San Diego, CA, USA).
Intracerebroventricular administration of the Aβ25–35
peptide
Aggregates of Aβ25–35 (Bachem AG, Weil am Rhein,
Germany) were prepared by incubating the peptides at a
concentration of 3 μg/μl in sterile water for 4 days at 37°C.
Subsequently, 5 μl of aggregated Aβ25–35 were injected
intracerebroventricularly (1.2 μl/min) with a 10-μl
Hamilton syringe using the following coordinates: 0.8 mm
posterior to the bregma, 1.5 mm lateral to the sagittalFigure 1 Design of the peptide Ilantide. (A) Tertiary structure model of
filled with purple) and IL-1 receptor type I (IL-1RI) (backbone and secondar
shown in red. (B) The IL-1Ra sequence with the mapped IL-1RI binding sitesuture and 3.8 mm beneath the surface of the brain. The
procedure was performed while the animals were under
anesthesia (i.p. fentanyl-fluanisone/midazolam at 0.3 ml/
100-g animal; that is, 23.6 μg of fentanyl, 0.75 mg of fluani-
sone and 375 μg midazolam per 100-g animal).
Social recognition test
Social memory in animals reflects the ability of individuals
to recognize conspecifics as familiar or unfamiliar. The so-
cial recognition test is a measure of short-term memory
and is suitable for studies of AD-like dementia because it
evaluates the function of neural structures that involve the
cholinergic system, which is impaired in AD [17,18]. The
animals were handled for 5 days, habituated to the test
cage and trained to interact with a juvenile rat. Three
groups of rats were used: a control group of untreated rats
(n = 11), an amyloid-/vehicle-treated group (n = 13) and
an amyloid/Ilantide-t-treated group (n = 12). Aggregated
amyloid-β protein fragment 25 to 35 (Aβ25–35; 15 μg) was
injected into the lateral ventricle. Ilantide-t (10 mg/kg) or
vehicle (1 ml/kg saline) was injected subcutaneously on
days 7, 9, 11, 13, 15, 17 and 19 after Aβ administration.
The social recognition test was conducted on day 20. Every
rat was tested three times. The first and second trials (T1
and T2) were performed with the same juvenile. In the
third trial (T3), the rats were tested with a new juvenile.
The trial lasted 4 minutes with a 30-minute intertrial inter-
val. During each trial, the investigative behavior of the adult
toward the juvenile (that is, licking, sniffing and chewing
the fur of the juvenile) was monitored with a video camera
and scored by an observer who was blinded to the treat-
ment of the animals. Animals that showed less than 40 sec-
onds of investigation of the juvenile during the initial trialthe complex between interleukin 1 receptor antagonist (IL-1Ra) (space
y structures in green). The location of the Ilantide peptide sequence is
and Ilantide motif is shown.
Figure 2 Interaction between Ilantide, interleukin 1β, and interleukin 1 receptor antagonist and soluble IL-1 receptor type I. Binding
was studied using surface plasmon resonance analysis. Approximately 2,500 to 3,000 resonance units (RUs) of interleukin 1β (IL-1β)
(A), IL-1 receptor antagonist (IL-Ra) (B) and Ilantide-t (C) were immobilized on a sensor chip. Binding is expressed as the response difference
between the binding of IL-1 receptor type I (IL-1RI) to the sensor chip with the immobilized peptide, IL-1β, or IL-Ra and a blank sensor chip. No
binding of any of the tested proteins and Ilantide-t was observed to the double-immunoglobulin (Ig) module (Ig1-Ig2) of the neural cell adhesion
molecule (NCAM) (negative control). (D) Binding of the IL-1RI ectodomain to immobilized IL-1β in the presence of the indicated concentrations
of Ilantide-t. The results from three experiments are expressed as mean RU ± SEM. **P < 0.01 and ***P < 0.001 compared with binding of IL-1RI
alone to IL-1β (one-way analysis of variance followed by the Newman-Keuls post hoc test).
Table 1 Affinity binding and rate constants of Ilantide,
interleukin 1β and interleukin 1 receptor antagonist to
interleukin 1 receptor type Ia
Ligands ka (M
-1 s-1) kd (s
-1) Kd (M)
Ilantide 1.84 ± 0.20 × 105 2.69 ± 0.58 × 10−3 2.75 × 10−8 ± 7 .86 × 10−9
IL-1Ra 1.47 ± 5.53 × 105 3.62 ± 0.65 × 10−3 4.80 × 10−8 ± 1.32 × 10−8
IL-1β 8.56 ± 2.79 × 105 7.53 ± 2.03 × 10−4 1.71 × 10−7 ± 7.07 × 10−9
aIL-1β, interleukin 1β; IL-1Ra, interleukin 1 receptor antagonist.
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tion ratio (RR). RRfamiliar was calculated as T2/(T1 + T2). T1
and T2 are the time spent investigating the juvenile animal
during the first and second trials. The time spent investi-
gating a novel juvenile (T3) was measured to confirm that
the effect seen with the familiar juvenile was specific to
cognition. In this case, RRnew was calculated as T3/(T1 +
T3). An RR value significantly less than the theoretical
value of 0.5, calculated by a one-sample t-test, was taken as
an indication of the presence of social memory.
Experimental autoimmune encephalomyelitis
Experimental autoimmune enchephalomyelitis was in-
duced in female Lewis rats by guinea pig myelin basic
protein (MBP) emulsified with CFA (Sigma-Aldrich) that
contained 1.0 mg/ml heat-inactivated M. tuberculosis.
While the animals were under inhalation anesthesia (3%
isoflurane; Baxter), 200 μl of an emulsion that contained200 μg of MBP were subcutaneously injected at the tail
base (dpi 0). Between dpi 0 and 21, weight and clinical
signs of EAE were recorded daily for all of the animals.
Clinical signs were scored as follows: 0 (no abnormality),
0.5 (weak tail), 1 (limp tail), 2 (mild palsy of one or both
hind legs), 3 (severe palsy of one or both hind legs),
4 (complete paralysis of one or both hind legs), 5 (par-
alysis of one or both hindlimbs and the beginning of
paralysis of the forelimbs) and 6 (moribund). Animals
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dpi 10 forward, the animals were treated once daily for 5
consecutive days with Ilantide-t (10 mg/kg, 1 ml/kg, s.c.)
or PBS (1.0 ml/kg s.c.). Only animals that reached a clin-
ical score ≥1 before dpi 14 were included in the study.
Data analysis
The statistical analysis was performed using one-way ana-
lysis of variance (ANOVA) followed by the Newman-Keuls
multiple-comparisons post hoc test or two-way ANOVA
followed by the Bonferroni post hoc test, a nonparametricFigure 3 Effect of Ilantide on nuclear factor κB activation induced by
type I (IL-1RI) or IL-6 receptor (IL-R6) were first treated with the Ilantide pep
IL-1RI (sIL-1RI), after which IL-1β-induced nuclear factor κB (NF-κB) or IL-6-in
activation was determined by enzyme-linked immunosorbent assay throug
alkaline phosphatase under the control of the interferon β minimal promo
was inhibited by IL-1Ra. (B) IL-1β-induced NF-κB activation was inhibited b
(D) IL-1β-induced NF-κB activation was inhibited by Ilantide-m. (E) Control
IL-1β-induced NF-κB activation. (F) Ilantide-t did not inhibit IL-6-induced ST
expressed as percentage ± SEM, in which control cells treated with either IL-1β
IL-1β-treated or IL-6-treated controls (one-way analysis of variance followed by Nt-test and a one-sample t-test when appropriate (GraphPad
Prism 5 software; GraphPad Software, La Jolla, CA, USA).
Results
Ilantide, a peptide modeled after the IL-1Ra binding site
for IL-1RI, binds to the ectodomain of IL-1RI with an
affinity comparable to the cytokine
Using a model of the tertiary structure of the IL-1Ra–
IL-1RI complex [PDB:1IRA] [19], we designed a peptide
ten amino acids long from the N terminus of IL-1Ra,
termed Ilantide (IL-1 antagonistic peptide), a part of theinterleukin 1β. HEK cells that overexpressed interleukin 1 receptor
tides, control peptides, IL-1 receptor antagonist (IL-1Ra) or soluble
duced signal transducer and activator of transcription 3 (STAT3)
h the induction of a reporter gene that expressed secreted embryonic
ter fused to five NF-κB binding sites. (A) IL-1β-induced NF-κB activation
y sIL-1RI. (C) IL-1β-induced NF-κB activation was inhibited by Ilantide-t.
peptides with scrambled or reversed sequences did not inhibit
AT3 activation. The results from four independent experiments are
or IL-6 alone were set at 100%. **P< 0.01 and ***P< 0.001 compared with
ewman-Keuls post hoc test).
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type I receptor (Figure 1). We studied the binding of
the peptide to IL-1RI by surface plasmon resonance
(SPR) analysis. IL-1β and IL-Ra were used as positive
controls. Ilantide-t, IL-1β and IL-1Ra bound to IL-1RI
(Figures 2A to 2C). The calculated affinity and rate
constants of these interactions are shown in Table 1.
IL-1Ra and Ilantide-t bound IL-1RI with apparent Kd
values within the same order of magnitude (4.8 × 10−8 M
and 2.75 × 10−8 M, respectively), whereas IL-1β had a
lower affinity for the receptor (1.71 × 10−7 M). As a
control, we also measured the binding of Ilantide-t,
IL-1β and Il-1Ra to a control Ig-like module molecule
that consisted of the double-Ig module of NCAM and
found no significant binding (Figures 2A to 2C).
Ilantide-t dose-dependently inhibited the binding
between IL-1RI and IL-1β (Figure 2D), indicating that
IL-1β and Ilantide competed for the same binding site
in IL-1RI.Figure 4 Effect of Ilantide on tumor necrosis factor α release from int
exposed to interleukin 1β (IL-1β) and treated with Ilantide peptides, contro
24 hours. The conditioned medium from macrophages was used to treat f
(TNF-α) in the conditioned medium was evaluated on the basis of fibrobla
from IL-1β-activated macrophages was inhibited by IL-1Ra. (B) TNF-α releas
(C) TNF-α release from IL-1β-activated macrophages was inhibited by Ilanti
by Ilantide-m. (E) Scrambled (scr) or reverse sequence control peptides did
results from four independent experiments are expressed as percentage ±
***P < 0.001 compared with macrophages treated with IL-1β only (one-wayIlantide inhibits the interleukin 1β-induced activation of
nuclear factor κB
The NF-κB signaling pathway plays a central role in
the regulation of IL-1-mediated inflammation [20]. We
assumed that Ilantide might inhibit NF-κB activation in-
duced by IL-1β because of the ability of Ilantide to out-
compete IL-1RI–IL-1β binding (Figure 2D). To test this
hypothesis, HEK cells that overexpressed IL-1RI were
used. NF-κB activation was induced by IL-1β. The cells
were treated with Ilantide, control peptides, IL-1Ra or
sIL-1RI, and the activation of NF-κB was determined by
ELISA. Similarly to IL-1Ra and sIL-1RI, both Ilantide-m
and Ilantide-t dose-dependently inhibited NF-κB activa-
tion induced by IL-1β (Figures 3A to 3D), whereas the
scrambled and reversed Ilantide-t peptides had no effect
(Figure 3E). In contrast, Ilantide-t did not inhibit STAT3
activation induced by IL-6 (Figure 3F), suggesting that
Ilantide specifically inhibits NF-κB activation induced by
IL-1β through binding to IL-1RI.erleukin 1β-activated macrophages. AMJ2-C8 macrophages were
l peptides, IL-1 receptor antagonist (IL-1Ra) or soluble IL-1RI (sIL-1RI) for
ibroblast cells for 24 hours, and the amount of tumor necrosis factor α
st cell survival in the presence of actinomycin D. (A) TNF-α release
e from IL-1β-activated macrophages was inhibited by sIL-1RI.
de-t. (D) TNF-α release from IL-1β-activated macrophages was inhibited
not inhibit TNF-α release from IL-1β-activated macrophages. The
SEM with untreated controls set at 100%. *P < 0.05, **P < 0.01 and
analysis of variance followed by Newman-Keuls post hoc test).
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necrosis factor α in macrophages
Macrophages are activated by T lymphocytes, resulting
in the production of proinflammatory cytokines (for ex-
ample, TNF-α and IL-1β). These cytokines trigger in-
flammatory cascades, thus leading to the activation of
inflammation [21,22]. To test whether Ilantide, IL-1β
or IL-1Ra would reduce TNF-α release from IL-1β-
activated macrophages, we used a mouse-derived macro-
phage cell line, AMJ2-C8. The cells were pretreated with
Ilantide, control peptides, IL-1Ra, sIL-1R or hydrocorti-
sone and stimulated by IL-1β or IFN-γ. The conditioned
medium from the macrophages was used to treat L929
cells, which, in the presence of actinomycin D, are
sensitive to picomolar concentrations of TNF-α [12].
The amount of TNF-α in the conditioned medium
was calibrated against fibroblasts exposed to standard
concentrations of TNF-α. As expected, IL-1β-induced
macrophage TNF-α production was completely inhibited
by 100 μM hydrocortisone (data not shown). Similarly to
IL-1Ra and sIL-1RI, Ilantide-m and Ilantide-t signifi-
cantly inhibited IL-1β-induced TNF-α secretion in mac-
rophages (Figures 4A to 4D), whereas the scrambled
Ilantide peptides had no statistically significant effect
(Figure 4E).
Ilantide promotes the survival of primary neurons
IL-1 mediates neuronal cell death during acute brain in-
jury [23], and IL-1Ra has neuroprotective effects on
cerebral ischemia, excitotoxicity and brain trauma in
various rodent models [24,25]. Therefore, we testedFigure 5 Effect of Ilantide and interleukin 1 receptor antagonist on su
apoptosis. The neurons were allowed to differentiate for 7 days in a high-
changing to a low-potassium medium (5 mM). Survival was estimated 48 h
interleukin 1 receptor antagonist (IL-1Ra) and IL-1β on cerebellar granule n
Ilantide-m on CGN apoptosis induced by 5 mM KCl. (C) The effect of Ilantid
four independent experiments are expressed as mean ± SEM with untreate
*P < 0.05 and **P < 0.01 compared with untreated cultures induced to und
Newman-Keuls post hoc test).whether Ilantide or IL-1Ra promotes neuronal cell
survival. Cerebellar granule neurons from 7-day-old rats
were differentiated for 7 days in a high-potassium
medium, after which the neurons were grown for 2
days in a low-potassium medium either the presence
or absence of insulin-like growth factor 1 (IGF-1;
positive control), Ilantide-m, Ilantide-t, IL-1Ra or IL-
1β. Cell death induced by potassium withdrawal was
inhibited by IGF-1 (Figure 5A). Treatment with IL-
1Ra, Ilantide-m and Ilantide-t, but not IL-1β,
concentration-dependently promoted CGN survival
(Figure 5). These results indicate that the inhibition
of IL-1RI in CGNs leads to an increase in neuronal
cell survival.
Ilantide stimulates neuritogenesis in cultures of primary
neurons
IL-1RI is widely expressed in the central nervous system,
including cerebellar, hippocampal and hypothalamic
neurons [26,27]. The firing rate of anterior hypothalamic
neurons is inhibited by IL-1β exposure [28]. To test the
effects of Ilantide-t, IL-1β, IL-1Ra and sIL-1RI on neur-
onal differentiation, CGNs were grown on fibroblast
cells in the absence or presence of these compounds at
various concentrations. We found that Ilantide-t, IL-1Ra
and sIL-1RI significantly induced neurite outgrowth
from 7-day-old CGNs in a dose-dependent manner
(Figures 6A to 6C), whereas IL-1β did not have neurito-
genic effects (Figure 6D).
We subsequently tested whether IL-1β interferes with
the neuritogenic effect of Ilantide and IL-1Ra. IL-1β atrvival of cerebellar granule neurons induced to undergo
potassium (40 mM) medium before apoptosis was induced by
ours later. (A) The effect of insulin-like growth factor 1 (IGF-1),
euron (CGN) apoptosis induced by 5 mM KCl. (B) The effect of
e-t on CGN apoptosis induced by 5 mM KCl. The results from at least
d cultures induced to undergo apoptosis by 5 mM KCl set at 100%.
ergo apoptosis (one-way analysis of variance followed by
Figure 6 Effect of Ilantide on neurite outgrowth from cerebellar granule neurons. Cerebellar granule neuron cultures were treated with
interleukin 1 receptor antagonist (IL-1Ra) (A), soluble interleukin 1 receptor type I (sIL-1RI) (B), Ilantide-t (C) or IL-1β (D) for 24 hours. The cultures
were fixed and immunostained with rabbit anti-rat growth-associated protein 43 (anti-GAP-43) primary antibodies and then with secondary Alexa
Fluor 488 goat anti-rabbit antibodies. (E) Effect of IL-1β on neurite outgrowth induced by IL-1Ra. (F) Effect of IL-1β on neurite outgrowth induced
by Ilantide-t. The results from three to four independent experiments are expressed as percentage ± SEM with untreated controls set at 100%,
corresponding to an average neurite length of 19.3 ± 4.1 μm. *P < 0.05 and **P < 0.01 compared with untreated controls (A to D) or cultures
treated with either IL-1Ra or Ilantide alone (E and F) by one-way analysis of variance followed by the Newman-Keuls post hoc test).
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ited the neuritogenic effect of both IL-1Ra and Ilantide-t
(Figures 6E and 6F). Thus, the inhibition of IL-1R signal-
ing resulted in the stimulation of neurite outgrowth.
Ilantide protects rat pancreatic islets from interleukin
1β-induced apoptosis independently of nitric oxide
To investigate the effectiveness and potency of Ilantide in
inhibiting IL-1-induced primary rat islet apoptosis, Ilantide
was added at a concentration of 8.68 × 10n nM as indicated
prior to exposure to a known proapoptotic concentration
of IL-1β of 8.68 nM (150 pg/ml) [29]. Consistent with pre-
vious findings [30], we observed that a maximally protective
effect of Ana of 64% inhibition against IL-1β-inducedapoptosis was obtained at a concentration of 8.68 × 104 nM
(Figure 7A), and this condition was used as a positive
control in the experiments with Ilantide.
Ilantide-m maximally inhibited IL-1β-induced apop-
tosis by 49% at 8.68 × 103 nM (Figure 7B). Ilantide-t
was a more effective antagonist of IL-1β-induced
apoptosis, with 93% inhibition, exceeding the antagonistic
effect of Ana, although Ilantide-t had lower potency
(8.68 × 106 nM) (Figure 7C).
In addition to preventing IL-1β-induced β-cell apoptosis,
Ana inhibits IL-1β-induced nitric oxide production [29].
Interestingly, none of the Ilantide peptides significantly
inhibited IL-1β-induced nitric oxide production at the con-
centrations that reduced IL-1β-induced apoptosis (Figure 8).
Figure 7 Effect of Ilantide on interleukin 1β-induced rat islet cell apoptosis. Rat pancreatic islets were preincubated for 30 minutes in the
absence or presence of various concentrations of anakinra (A), Ilantide-m (B) or Ilantide-t (C) and then exposed to 8.68 nM interleukin 1β (IL-1β)
for 24 hours. Cytokine-induced apoptosis was determined by cell death detection enzyme-linked immunosorbent assay. Apoptosis rates are
presented as fold induction compared with untreated control islets (white bars). The data from four independent experiments are presented as
mean ± SEM. *P < 0.05 and **P < 0.01 compared with cultures treated with IL-1β alone (one-way analysis of variance followed by Dunnett’s post
hoc test).
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The time course of the peptide concentrations in plasma
samples collected from rats after a single subcutaneous in-
jection at a 10 mg/kg dose is shown in Figure 9. Ilantide-t
was detected in plasma 20 minutes after administration
(5,816 ± 44 ng/ml) and remained detectable for up to 30
hours (111 ± 3.3 ng/ml). Twenty minutes after subcutane-
ous administration, the peptide concentration in plasma av-
eraged approximately 6 μg/ml, and its half-life was
calculated as approximately 2 hours. The peptide concentra-
tion in CSF was 125 ± 13 ng/ml 30 minutes after systemic
administration. Thus, the ratio between the Ilantide concen-
tration in plasma (measured at 20 minutes) and the Ilantide
concentration in CSF (measured at 30 minutes) was 55.
Ilantide reduces inflammation in collagen-induced
arthritis model
IL-1 is a major pathogenic cytokine in the development of
rheumatoid arthritis [31]. The concentration of IL-1 in sera
of rats with CIA is already elevated during the preclinicalFigure 8 Effect of Ilantide on interleukin 1β-induced nitric oxide prod
Ilantide-t (C), inhibited interleukin 1β (IL-1β)-induced nitric oxide productio
the experiments presented in Figure 7. The results of four independent exp
treated with IL-1 alone (one-way analysis of variance followed by Dunnett’sstage of the disease, and it reaches a maximal level during
the first 4 to 5 days after disease onset [32]. Therefore, we
used a treatment regimen that specifically covered this
period. Figure 10 illustrates the dynamics of the clinical state
(Figure 10A) and cumulative clinical scores (Figure 10B) in
rats with CIA. Ilantide-t significantly attenuated the severity
of CIA on dpi 10 to 16 compared with the vehicle-treated
group (t = 2.1, df= 31; P < 0.05 by unpaired t-test).
Ilantide strongly reduces lipopolysaccharide-induced
behavioral changes
Two-way ANOVA did not reveal significant differences be-
tween the veh/veh, veh/Ila and veh/Ana groups (F2,72 = 1.04,
P= 0.37), indicating that Ilantide-t and Ana did not modify
social behavior per se (Figure 11A). LPS significantly de-
pressed social activity for 8 hours following compound ad-
ministration (F1,72 = 54.59, veh/veh vs. LPS/veh; P < 0.0001).
Ilantide-t counteracted the onset of sickness behavior and
attenuated social depression compared with vehicle-treated
animals (F1,76 = 13.92, LPS/veh vs. LPS/Ila; P= 0.001). Nouction. Anakinra (A) but none of the peptides, Ilantide-m (B) or
n. Nitrites were measured in the supernatants using data derived from
eriments are shown. *P < 0.05 and **P < 0.01 compared with cultures
post hoc test).
Figure 9 Time course of Ilantide concentration in plasma and
cerebrospinal fluid after a single subcutaneous injection of 10
mg/kg. Peptide concentrations were measured by performing a
competitive enzyme-linked immunosorbent assay. The data are
expressed as mean ± SEM. CSF, cerebrospinal fluid.
Figure 10 Ilantide attenuates the severity of arthritis in animals with
by an intradermal injection of 250 μg of collagen II emulsified in complete
(dpi 8), before the onset of clinical signs, all of the animals were randomly
(dpi 8 to 15) with 10 mg/kg Ilantide-t (n = 17) or 1 ml/kg phosphate-buffer
during the entire treatment period, the values are expressed as the area un
set at dpi 8. The data are expressed as mean ± SEM. *P < 0.05 by unpaired
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(Figure 11B).
One-way ANOVA showed that LPS decreased body
weight 24 hours after LPS injection (P < 0.001, LPS/veh vs.
Veh/Veh, Newman-Keuls post hoc test). Ilantide-t and
Ana attenuated the anorexigenic effect of LPS (P < 0.05,
LPS/veh vs. LPS/Ila and LPS/veh vs. LPS/Ana, Newman-
Keuls post hoc test) (Figure 11C). The effect of Ilantide-t
on LPS-induced sickness behavior was accompanied by an
increase in IL-10 plasma levels 2 hours after LPS adminis-
tration (F1,42 = 6.03, P < 0.01) (Figure 11D). There was a
tendency toward reduction of levels of proinflammatory
cytokines (IL-6 and IFN-γ) 6 hours following LPS injec-
tion, although the effect was not statistically significant
(Figure 11D).
Ilantide delays clinical signs of experimental autoimmune
enchephalomyelitis
To further investigate the effect of Ilantide on neuroin-
flammation, EAE (that is, an animal model of multiple
sclerosis) was induced in rats by injecting MBP in CFA.
Following the induction of EAE, the animals’ weight, clin-
ical signs of EAE and survival were recorded. The first
clinical signs of EAE appeared on dpi 10. From dpi 10 to
14, the animals were treated daily with either Ilantide or
vehicle. Treatment with Ilantide-t had no significant ef-
fects on weight change or survival (data not shown). As
shown in Figure 12, however, the clinical signs of EAE
were attenuated by Ilantide-t. In Figure 12, the data from
individual animals are aligned according to the first ap-
pearance of clinical signs. On the first and second days,collagen-induced arthritis. (A) Collagen-induced arthritis was induced
Freund’s adjuvant (125 μg M. tuberculosis). On day postimmunization 8
divided into two groups and subcutaneously dosed daily for 8 days
ed saline vehicle (n = 16). (B) To evaluate cumulative clinical scores
der the curve for each group during dpi 10 to 15 with the baseline
t-test.
Figure 11 Ilantide attenuates the decrease in social activity and increases plasma levels of interleukin 10 in lipopolysaccharide-
induced neuroinflammation. Ilantide-t (Ila; 10 mg/kg), anakinra (Ana; 100 mg/kg) or vehicle (Veh; 1 ml/kg) was subcutaneously injected
simultaneously with an intraperitoneal injection of either lipopolysaccharide (LPS) (250 μg/kg) or vehicle (1 ml/kg). Baseline social activity was
recorded for 4 minutes for all of the animals at 0 hours. The duration of social interaction at each time point is expressed as a percentage of
baseline values and was averaged for each experimental group. The data are expressed as mean ± SEM. (A) Social activity of rats in control
groups. (B) Social activity of rats in LPS-treated and veh/veh groups (SEM for LPS/Ana group not presented). *P < 0.05 and ***P < 0.001 compared
with control (veh/veh). +P < 0.05 and ++P < 0.01 compared with LPS/Ila group. (C) Weight gain is expressed as the difference from the body
weight measured at 0 and 24 hours after LPS injection. *P < 0.05 (one-way analysis of variance (ANOVA) followed by Newman-Keuls post hoc test).
(D) Plasma levels of interleukin 6 (IL-6), interferon γ and IL-10. **P < 0.01 (B and D), by two-way ANOVA followed by Bonferroni post hoc test.
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t-treated animals than in vehicle-treated animals. At later
time points, however, no difference was found between
the mean clinical signs in the two groups. These results
show that the treatment of EAE with Ilantide attenuated,
but did not prevent, the development of EAE.
Ilantide reduces social memory deficits induced by
amyloid-β
Aβ is known to induce deficits in social memory. There-
fore, we tested whether Ilantide can rescue Aβ-inducedsocial memory impairment. The rats were administered
Aβ25–35, followed by administration with either Ilantide-
t or vehicle. No significant intergroup difference in
social activity was observed during the first trial, sug-
gesting that Aβ and Ilantide-t did not influence investi-
gatory activity per se (F2,32 = 0.94; P = 0.4 by one-way
ANOVA) (data not shown). Social memory was mea-
sured as a decrease in the time that an adult rat spent
investigating the same (that is, familiar) juvenile during
the second trial compared with the first trial. The social
recognition RRfamiliar value was <0.5 in the untreated
Figure 12 Ilantide delays the progression of experimental
autoimmune encephalomyelitis. Experimental autoimmune
encephalomyelitis (EAE) was induced in 30 animals, from among
which 22 developed clinical signs of EAE (12 from the control group
and 10 from the group treated with Ilantide-t). Clinical signs were
evaluated daily. All of the data were aligned according to the onset
of clinical signs and are presented as mean ± SEM. When the animals
were killed, their clinical scores on the day they were killed were
maintained at all subsequent time points. **P < 0.01 and ***P < 0.001
(two-way repeated-measures analysis of variance followed by the
Bonferroni post hoc test).
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(Figure 13). Animals in the Aβ/veh group exhibited a sig-
nificant deficit in social memory. The rats in this group
failed to recognize the juvenile during the second trial.
RRfamiliar did not differ from 0.5 (t = 0.44, df = 11; P = 0.67
by one-sample t-test) and significantly differed from the
RRfamiliar in the control group (P < 0.001 by one-way
ANOVA followed by the Newman-Keuls post hoc test).
Treatment with Ilantide-t counteracted the development
of cognitive impairment. The RRfamiliar in this group
was significantly lower than the theoretical value of 0.5
(t = 4.12, df = 11; P = 0.002 by one-sample t-test) and the
value in the Aβ/veh group (P < 0.05 by one-way ANOVA
followed by the Newman-Keuls post hoc test). The Aβ/
Ilantide-treated rats were still able to recognize a new, un-
familiar juvenile during the third trial (that is, the RRnew
value did not differ from 0.5) (t = 0.7, df = 11; P = 0.5 by
one-sample t-test), indicating that Ilantide ameliorated the
social memory deficit in Aβ-treated animals.
Discussion
A critical role for IL-1 in the pathogenesis of acute and
chronic inflammation has been well-documented [33-35].IL-1RI blockade is one of the current strategies used in
the treatment of IL-1-induced conditions [1], and an IL-RI
receptor antagonist, Ana, has already been approved for
the treatment of some of these conditions. Despite the
high efficacy of Ana, however, this drug has some disad-
vantages, such as a short-lasting therapeutic effect in 20%
of patients with rheumatoid arthritis [36], local injection
reactions (for example, erythema, ecchymosis, inflamma-
tion and pain [37]) and in some cases depression [38].
Furthermore, the absence of an effect of peripheral admin-
istration of Ana on neuroinflammation observed in the
present study should be added to the list of Ana’s disad-
vantages, although further testing with other Ana doses is
needed to substantiate this finding.
The aim of the present study was to develop a syn-
thetic low-molecular-weight antagonist of IL-1RI that is
effective in the treatment of not only peripheral inflam-
mation but also neuroinflammation. We found that a
peptide termed Ilantide, derived from the N terminus of
human IL-1Ra, mimics important characteristics of
IL-1Ra. Thus, Ilantide binds to IL-1RI with an affinity
comparable to that of IL-1Ra and with higher affinity than
IL-1β. Importantly, Ilantide inhibits the binding of IL-1β
to IL-1RI. Signaling from the IL-1/IL-1RI/Il-1RAcP com-
plex is known to activate the NF-κB pathway [20]. We
found that Ilantide inhibited NF-κB activation. We also
found that Ilantide, similarly to IL-1Ra, inhibited the secre-
tion of TNF-α by macrophages, thus antagonizing an im-
portant mechanism of the proinflammatory action of IL-1.
IL-1 induces apoptosis in insulin-producing pancreatic
β-cells, and the administration of Ana in patients with
type 2 diabetes mellitus improves β-cell function [39].
We investigated the protective potency of Ilantide
against the IL-1-induced apoptosis of pancreatic islets
and compared it to the potency of Ana. Ilantide-t in high
molar excess reduced IL-1-induced apoptosis by 93%,
which was 1.5× the maximal effect of Ana. Unlike Ana,
however, the effect of Ilantide was not associated with
inhibition of IL-1-induced nitric oxide production, which
is consistent with the less effective inhibition of NF-κB
activation compared with IL-1Ra (Figures 3A and 3C).
The molecular mechanism that underlies this discrep-
ancy is unclear, but it may be related to the lower steric
hindrance that Ilantide exerts on the IL-1/IL-1RT1/IL-
1RAcP interaction complex compared with IL-1Ra, thus
allowing the escape of certain parts of IL-1 signaling. IL-
1Ra is known to interact with all three IL-1RI receptor
domains, whereas the Ilantide sequence motif includes
only two residues from the binding site that is involved
in the interaction with the Ig3 domain (see Figure 1B).
Signaling via IL-1RI occurs only if the ligand-bound re-
ceptor associates with the IL-1RAcP protein. Two loops
in IL-1Ra (β4–β5 and β11–β12) are determinants of the
antagonism of IL-1Ra that prohibit ligand-bound IL-1RI
Figure 13 Ilantide reduces social memory deficits induced by amyloid-β. Ilantide-t (10 mg/kg; n = 12) or vehicle (saline, 1 ml/kg; n = 13)
was subcutaneously injected on days postimmunization (dpi) 7, 9, 11, 13, 15, 17 and 19 after intracerebroventricular administration of aggregated
Aβ25–35 (15 μg). The control group consisted of 11 rats. The social recognition test was performed on dpi 20. Social memory was estimated as the
recognition ratio (RR). RRfamiliar was calculated as T2/(T1 + T2). T1 and T2 are the times spent investigating the same juvenile animal during the first
and second trials, respectively. RRnew was calculated as T3/(T1 + T3). T1 and T3 are the times spent investigating the different juvenile animals
during the first and third trials, respectively. An RR value significantly less than the theoretical value of 0.5 obtained by one-sample t-test was
taken as an indication of the presence of social memory. **P < 0.01 and ***P < 0.001 by one-sample t-test compared with theoretical value of
0.5. +P < 0.05 and +++P < 0.001 by one-way analysis of variance followed by the Newman-Keuls post hoc test.
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these two loops, and the actual mechanism of the Ilantide-
induced inhibition of IL-1 signaling might be somewhat
different from that of Ana. From the pharmaceutical per-
spective, the chemically produced Ilantide peptide has a
number of advantages over Ana (which belong to recom-
binant biologics), such as better penetration through the
BBB, better stability and less batch-to-batch variations.
Rheumatoid arthritis is triggered and maintained by
cascades of inflammatory mediators. The current treat-
ments for RA include neutralizing antibodies and antag-
onists of mediators of inflammation, particularly IL-1
and TNF-α. We observed a positive effect of Ilantide in
the CIA model that resembled several aspects of
rheumatoid arthritis [41] when treatment began in the
preclinical stage that corresponds to the first elevation
of IL-1 levels in the blood. This result suggests that the
blockade of IL-1 signaling with Ilantide may be an effect-
ive treatment for rheumatoid arthritis patients.IL-1 receptors are well-known to be expressed in the
brain [42,43], and IL-1 is a key mediator of neuroinflam-
mation. IL-1β is synthesized and released by microglia
and astrocytes and regulates IL-1RI expression in neu-
rons and astrocytes [44]. The neuron-specific effects of
IL-1β were recently shown to be mediated by a novel
isoform of IL-1RAcP—IL-1RAcPb, which results in the
activation of p38MAPK, but not NF-κB, in hippocampal
neurons [45]. However, the role of neuronal p38MAPK
signaling is poorly understood [46]. We found that both
Ilantide and recombinant IL-1Ra induced neuritogenesis
and promoted the survival of primary neurons. The
neuronal cultures used in our experiments did not con-
tain microglial cells [47] and included less than 5% as-
trocytes, which could be a source of IL-1 that affects the
ability of neurons to differentiate and survive. Ilantide
and IL-1Ra likely inhibited the effect of traces of IL-1 on
IL-1RI, thereby triggering neuritogenesis and survival
mechanisms.
Klementiev et al. Journal of Neuroinflammation 2014, 11:27 Page 16 of 18
http://www.jneuroinflammation.com/content/11/1/27Intraperitoneal injections of LPS have been shown to
induce IL-1 production in peripheral activated mono-
cytes and macrophages, as well as in the brain (that is,
the hypothalamus and hippocampus) [48]. IL-1 overpro-
duction induces anorexia and depression, causing body
weight loss and a reduction of social activity in rodents.
One injection of Ilantide significantly ameliorated these
effects of LPS, a potent inducer of IL-1 production. This
peptide effect was accompanied by an increase in the
plasma levels of the anti-inflammatory cytokine IL-10 in
LPS-treated animals. We have shown in the present
study that Ilantide crossed the BBB, which explains the
protective effects of Ilantide on neuroinflammation. The
ratio between Ilantide concentration in plasma and its
concentration in CSF was 55, which is in good agree-
ment with our previous results obtained for other pep-
tides, the peptide derived from fibroblast growth factor
receptor (plasma/CSF ratio = 10) [49] and the peptide
derived from the NCAM (plasma/CSF ratio = 40) [50].
Reasonable BBB penetration of the peptide can also ex-
plain the cerebroprotective effect of Ilantide in the
model of AD. IL-1 contributes to neuroinflammation
during the progression of AD. Intracerebroventricular
administration of aggregated Aβ25–35 induces neuroin-
flammation, which is manifested by the activation of
microglia and astrocytes, neuronal damage and cognitive
impairments [51] and overproduction of IL-1 in acti-
vated microglia [52]. Our in vitro data show that Ilantide
promoted neural survival and neuritogenesis, which is
an essential component of neuroplasticity and can ex-
plain the mnemotropic effect of Ilantide in the AD
model.
EAE is often used as a model of multiple sclerosis in
humans. The activation of endogenous IL-1 is involved
in the progression of EAE, and IL-1Ra can reduce the
clinical signs of the disease [53,54]. Comparisons of the
beneficial effects of IL-1Ra and Ilantide showed that a
more profound effect of IL-1Ra was achieved by a
26× higher total dose per kilogram compared with Ilan-
tide in the present study [54]. Others have shown that
the same dose [55] or a lower dose [56] of IL-1Ra has
no significant effect on clinical scores.
In conclusion, we have identified a novel 10–amino
acid peptide antagonist of IL-1, Ilantide, that binds to
IL-1RI and inhibits the IL-1-induced activation of NF-κB
and secretion of TNF-α by macrophages. The peptide
protected pancreatic islets from IL-1β-induced apoptosis
and reduced inflammation in CIA. The Ilantide peptide
penetrated the BBB, diminished the deficit in social ac-
tivity and memory in LPS- and amyloid-induced neuro-
inflammation and delayed the development of EAE in
rats. We propose that this novel IL-1 antagonist can be
used as an alternative to other IL-1 blockers to inhibit a
variety of inflammatory conditions.Abbreviations
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